TOP TEN perturbations for 1555265_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1555265_at
Selected probe(set): 233371_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1555265_at (233371_at) across 6622 perturbations tested by GENEVESTIGATOR:

systemic onset JIA study 4 / juvenile enthesitis related arthritis study 2 (ERA)

Relative Expression (log2-ratio):4.36218
Number of Samples:3 / 3
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).

systemic onset JIA study 4 / oligoarticular JIA study 3

Relative Expression (log2-ratio):4.331943
Number of Samples:3 / 12
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control oligoarticular JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with persistent oligoarthritis (oligoarticular JIA).

systemic onset JIA study 4 / normal PBMC sample

Relative Expression (log2-ratio):4.2369423
Number of Samples:3 / 27
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / oligoarticular JIA study 2

Relative Expression (log2-ratio):4.22622
Number of Samples:3 / 12
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control oligoarticular JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of persistent oligoarticular juvenile idiopathic arthritis (JIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 5 / normal PBMC sample

Relative Expression (log2-ratio):4.2001934
Number of Samples:3 / 27
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / polyarticular JIA study 4 (RF negative)

Relative Expression (log2-ratio):3.986682
Number of Samples:3 / 17
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control polyarticular JIA study 4 (RF negative)
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA, RF neg.). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / polyarticular JIA study 6

Relative Expression (log2-ratio):3.9160843
Number of Samples:3 / 14
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control polyarticular JIA study 6
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative polyarthritis (RF- polyarthritis/RF- polyarticular JIA).

systemic lupus erythematosus study 3 / normal blood sample

Relative Expression (log2-ratio):-3.7976837
Number of Samples:89 / 30
Experimental systemic lupus erythematosus study 3
Blood samples derived from patients with anti-ribonuclear protein-positive (anti-RNP+) systemic lupus erythematosus (SLE).
Control normal blood sample
Blood samples from healthy individuals.

sickle cell disease study 2 (Pax) / normal blood sample

Relative Expression (log2-ratio):3.4244576
Number of Samples:5 / 5
Experimental sickle cell disease study 2 (Pax)
Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step.
Control normal blood sample
Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):3.2836647
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.